UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Earliest event reported) January 8, 2006
BIOPHAN TECHNOLOGIES, INC.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-26057 82-0507874
------------------------ ------------------ ------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) file number) Identification No.)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
----------------------------------------------- -------------
(Address of principal executive offices) (Zip code)
(585) 214-2441
--------------------------------
(Registrant's telephone number
including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On January 8, 2006, we entered into an agreement (the "Amendment") to amend the
Stock Purchase Agreement (the "Agreement") dated as of May 27, 2005 (the "Stock
Purchase Agreement") between us SBI Brightline XI, LLC, a California limited
liability company ("SBI"). The Amendment was intended to remove from the Stock
Purchase Agreement any ambiguity regarding the date and time at which SBI is
obligated to purchase Tranche Shares (as such term is defined in the Stock
Purchase Agreement) and to make clear that the Tranche Closing Dates (as such
term is defined in the Stock Purchase Agreement), once determined by use are not
subject to negotiation between us and SBI Pursuant to the Stock Purchase
Agreement, as amended, SBI is obligated to purchase, on the dates we elect, up
to 10,000,000 shares of our Common Stock for an aggregate purchase price of $30
million. The shares are to be sold in tranches of 1,000,000 shares each at
increasing per share purchase prices ranging from $2.00 to $4.00 (for a weighted
average price of $3.00 per share). Except for the requirement to sell the
tranches in order and the requirement that the resale of the shares be
registered as described below, there is no limitation on when we may require SBI
to purchase the shares included in any tranche. We are not obligated to sell any
shares to SBI unless and until we make an election to do so. SBI is not
obligated to purchase shares pursuant to the Stock Purchase Agreement unless the
resale of the shares by SBI is registered under the Securities Act of 1933. We
expect to exercise our right to sell shares to SBI when and as we deem necessary
to fund our ongoing business operations and development activities, based on our
cash requirements, revenues from operations, third party research support,
licenses and potential strategic investments, and the availability of debt or
equity financing from other sources on more favorable terms.
The Stock Purchase Agreement was filed as Exhibit 4.21 to our amended Annual
Report on for 10-KSB/A for the fiscal year ended February 28, 2005. The
Amendment is filed herewith as Exhibit 4.1. The foregoing description of the
Amendment and the relevant portions of the Stock Purchase Agreement are
qualified in its entirety by reference to such Exhibits.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
----------------- --------------------------------------------------------------
Exhibit Number Description of Exhibit
----------------- --------------------------------------------------------------
4.1 Amendment No. 1, dated January 8, 2006, to Stock Purchase
Agreement by and between Biophan Technologies, Inc. and SBI
Brightline XI, LLC
----------------- --------------------------------------------------------------
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
/s/ Michael L. Weiner
Date: January 9, 2006 -------------------------------------
Michael L. Weiner
President and CEO